Research peptides are not approved for human use in most countries including India. This page is for educational purposes only. Consult a physician before use.
What is Hexarelin?
Hexarelin (His-D-2-Me-Trp-Ala-Trp-D-Phe-Lys-NH2) is a synthetic hexapeptide in the GHRP (Growth Hormone Releasing Peptide) family. It is structurally derived from GHRP-6 but with amino acid modifications that increase its potency at the GHS-R1a (ghrelin) receptor significantly above its predecessor.
Hexarelin produces the strongest GH pulse of any known GHRP — including GHRP-2, GHRP-6, and ipamorelin. This potency was initially considered advantageous, but the accompanying cortisol elevation and rapid receptor desensitization have made it less suitable for ongoing clinical use compared to ipamorelin's cleaner profile.
What makes hexarelin uniquely interesting in the longevity space is a completely separate discovery: it has significant cardioprotective effects through GH-independent mechanisms via CD36 receptor binding in cardiac tissue.
GH-Releasing Potency and the Cortisol Problem
Hexarelin's GH pulse is impressive:
- In healthy young adults, hexarelin at 2 mcg/kg produces GH peaks of 40–80 ng/mL — compared to ipamorelin's typical 15–25 ng/mL
- It is more potent than GHRP-2 and far more potent than GHRP-6 on a per-microgram basis
But this potency comes with significant trade-offs:
- Cortisol elevation: Hexarelin causes the highest cortisol increase of any GHRP — this is counterproductive for longevity and body composition goals, as cortisol is catabolic and inflammatory
- Prolactin elevation: Significant prolactin increase with hexarelin, more than other GHRPs
- Tachyphylaxis: Hexarelin desensitizes the GHS-R1a receptor faster than any other GHRP — after 4–6 weeks of daily use, the GH response diminishes substantially
The Cardioprotective Mechanism: GH-Independent CD36 Binding
This is hexarelin's most scientifically interesting property. Research beginning in the late 1990s demonstrated that hexarelin's cardiac effects cannot be entirely explained by GH release:
- Hexarelin reduced myocardial damage in ischemia/reperfusion models even in animals where the pituitary had been removed (hypophysectomized) — proving the effect is not mediated through GH
- The mechanism involves binding to CD36, a scavenger receptor expressed in cardiac myocytes and other tissues
- CD36 binding activates cardioprotective signaling including PI3K/Akt pathways that suppress apoptosis and reduce infarct size
- Hexarelin also appears to reduce cardiac fibrosis and improve ventricular function in heart failure models
No other GHRP shares hexarelin's CD36-mediated cardioprotection. This is a completely separate mechanism from its GH-releasing activity and represents one of the few examples of a peptide with two entirely independent mechanisms of action relevant to longevity medicine.
Human Cardiac Data
A limited but suggestive human data set exists:
- Laron et al. (1994) demonstrated GH stimulation in GH-deficient children, confirming human receptor activity
- Studies in patients with heart failure (Broglio et al.) showed improved cardiac function parameters after hexarelin administration, suggesting the cardioprotective mechanism may translate to humans
- No large RCTs have been conducted for hexarelin's cardiac indications — the cardiac data remains preclinical and small-trial
GHRP Comparison
| Peptide | GH Potency | Hunger Stimulation | Cortisol Elevation | Tachyphylaxis | Unique Feature |
|---|---|---|---|---|---|
| Hexarelin | Strongest | Moderate | High | Fastest | CD36 cardioprotection |
| GHRP-2 | Very strong | Moderate | Moderate | Moderate | Better than GHRP-6 profile |
| GHRP-6 | Strong | Strong (2–3×) | Significant | Moderate | Original GHRP template |
| Ipamorelin | Moderate | Minimal | None | Slowest | Highest selectivity — preferred long-term |
Practical Use Context
Given hexarelin's profile, practical applications are narrow:
- Short cycles only: 4–6 weeks maximum before receptor desensitization becomes significant
- Lower frequency: Some practitioners use hexarelin every other day or 3×/week to slow tachyphylaxis
- Cardiac applications: Speculative longevity use for cardiovascular protection, particularly interesting for individuals with cardiac risk factors
- Not for daily long-term use: The cortisol elevation and tachyphylaxis make daily ongoing use counterproductive
- Dose: 100–200 mcg subcutaneously per injection
Frequently Asked Questions
Hexarelin vs ipamorelin — which is more potent?
Hexarelin produces a stronger GH pulse than ipamorelin in most studies — it is among the most potent GHRPs known. However, hexarelin also causes significant cortisol and prolactin elevation and desensitizes faster. Ipamorelin is more selective and suitable for ongoing daily use; hexarelin is more potent but less appropriate for long-term daily protocols.
Does hexarelin protect the heart independently of GH?
Yes — this is hexarelin's most unique property. It binds to CD36 receptors in cardiac tissue through a GH-independent pathway, reducing myocardial damage in ischemia/reperfusion animal models. This cardiac protective effect has been demonstrated even in hypophysectomized animals, confirming it is independent of GH release.
Why does hexarelin cause cortisol elevation?
Hexarelin binds GHS-R1a receptors with less selectivity than ipamorelin, also activating pathways that stimulate ACTH release from the pituitary, which then triggers cortisol production. This is the same off-target effect seen with GHRP-6 and GHRP-2, and why ipamorelin was specifically engineered to avoid it.
Hexarelin dosage and cycle length?
Common protocols use 100–200 mcg subcutaneously 1–2 times per day. Due to rapid tachyphylaxis, cycle lengths should be shorter — typically 4–6 weeks maximum. A washout period of equal length is recommended before restarting.